Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana

American Journal of Tropical Medicine and Hygiene

Volumn 88, Issue 1, 2013, Pages 153-156

  Ordaz Farias, Alejandro ^a   Muñoz Garza, Fania Z ^a   Sevilla Gonzalez, Farah K ^a   Arana Guajardo, Ana ^a   Ocampo Candiani, Jorge ^a   Treviño Garza, Nancy ^b   Becker, Ingeborg ^c   Camacho Ortiz, Adrian ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Secretary of Health   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MEGLUMINE; MILTEFOSINE; OMEPRAZOLE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HUMAN TISSUE; LARYNGOSCOPY; LEISHMANIA MEXICANA; MALE; NONHUMAN; SKIN BIOPSY; SKIN DISEASE; SKIN LEISHMANIASIS; STRIDOR; TREATMENT DURATION;

ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA MEXICANA; LEISHMANIASIS, DIFFUSE CUTANEOUS; PHOSPHORYLCHOLINE;

LEISHMANIA MEXICANA MEXICANA; LEISHMANIA SP.;

EID: 84872356118     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.11-0592     Document Type: Article

References (23)

1. Maroli M, Khoury C, 2004. Prevention and control of leishmaniasis vectors: current approaches. Parassitologia 46: 211-215. (Pubitemid 40063881)
2. World Health Organization. Control of Leishmaniases. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. Available at: http://whqlibdoc.who.int/trs/WHO-TRS-949-eng.pdf. Accessed August 2, 2012.
3. Mondal S, Bhattacharya P, Ali N, 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919-944.
4. Richard JV, Werbovetz KA, 2010. New antileishmanial candidates and lead compounds. Curr Opin Chem Biol 14: 447-455.
5. Almeida OL, Santos JB, 2011. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: asystematic literature review. An Bras Dermatol 86: 497-506.
6. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, Matos N, Mendoza I, Pratlong F, Ravel C, Convit J, 2007. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 156: 1328-1335. (Pubitemid 47029811)
7. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, Almeida RP, Mobashery N, Johnson WD Jr, Carvalho EM, 2002. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186: 1829-1834. (Pubitemid 35463517)
8. Ruiz JH, Becker I, 2007. CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 29: 671-678. (Pubitemid 350179394)
9. Hernández-Ruiz J, Salaiza-Suazo N, Carrada G, Escoto S, 2010. RuizRemigio A, Rosenstein Y, Zentella A, Becker I. CD8 cells of patients with diffuse cutaneous leishmaniasis display funconal exhaustion: the latteris reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis 4: e871.
10. Mayrink W, Botelho AC, Magalhães PA, Batista SM, Lima Ade O, Genaro O, Costa CA, Melo MN, Michalick MS, Williams P, Dias M, Caiaffa WT, Nascimento E, Machado-Coelho GL, 2006. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 39: 14-21.
11. Pereira LI, Dorta ML, Pereira AJ, Bastos RP, Oliveira MA, Pinto SA, Galdino H Jr, Mayrink W, Barcelos W, Toledo VP, Lima GM, Ribeiro-Dias F, 2009. Increase of NK cells and proinflammatory monocytes are associated with the clinical improvementof diffuse cutaneous leishmaniasis after immunochemotherapy with BCG/Leishmania antigens. Am J Trop Med Hyg 81: 378-383.
12. Okwor I, Uzonna JE, 2009. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy. 1: 765-776.
13. Simpson MH, Mullins JF, Stone OJ, 1968. An Autochthonous Case in Texas and the Mexican States of Tamaulipas and Nuevo Leon. Arch Dermatol 97: 301-303.
14. Trainor KE, Porter BF, Logan KS, Hoffman RJ, Snowden KF, 2010. Eight cases of feline cutaneous leishmaniasis in Texas. Vet Pathol 47: 1076-1081.
15. McHugh CP, 2010. Cutaneous leishmaniasis in Texas. J Am Acad Dermatol 62: 508-510.
16. Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ, 2008. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol 58: 650-652.
17. Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A, 2008. A comparative study between the efficacy of systemic meglumineantimoniate therapy with standard or low dose plus omeprazole in the treatment of cutaneous leishmaniasis. J Vector Borne Dis 45: 287-291.
18. Van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M, 2010. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184-194.
19. Shakya N, Sane SA, Vishwakarma P, Bajpai P, Gupta S, 2011. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv. Acta Trop 119: 188-193.
20. Shamsi Meymandi S, Javadi A, Dabiri S, Shamsi Meymandi M, Nadji M, 2011. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumineantimoniate, imiquimod or combination therapy. Arch Iran Med 14: 238-243.
21. Kashani MN, 2007. Evaluation of meglumineantimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol 17: 513-515. (Pubitemid 350207162)
22. Soto J, Toledo J, Valda L, BalderramaM, Rea I, Parra R,Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350-356. (Pubitemid 46147616)
23. Calvopina M, Gomez E, Sindermann H, Cooper P, Hashiguchi Y, 2006. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 75: 1074-1077. (Pubitemid 351627483)